OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of ENTYVIO ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License ...